ctDNA Increase May Predict Regorafenib Response in Advanced CRC

In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.

Related Content:

American Association for Cancer Research Annual Meeting (AACR)Colorectal CancerGastrointestinal Cancer

Tanio S. Bekaii-Saab, MD, on Panitumumab/FOLFOX as Standard for Left-Sided, RAS Wild-Type CRC From the PARADIGM Trial

Tanio S. Bekaii-Saab, MD, Forecasts Treatment Landscape of CRC as More Targeted Regimens Become Available

Tanio S. Bekaii-Saab, MD, Reflects on How Targeted Therapy Regimens Will Push Precision Approaches in CRC